What is Human Longevity?
Human Longevity, Inc. (HLI) is a global leader in advancing precision medicine with a focus on healthy aging, commonly referred to as longevity medicine. Established in 2013, the company leverages its expertise to drive innovation in the burgeoning field of longevity. The recent investment will fuel HLI's growth within the U.S. market and support its strategic expansion into the Kingdom of Saudi Arabia and Southeast Asia, underscoring its global ambitions in the health and wellness sector.
How much funding has Human Longevity raised?
Human Longevity has raised a total of $370.8M across 5 funding rounds:
Series A
$80M
Series B
$220M
Other Financing Round
$30M
Debt
$1M
Series B
$39.8M
Series A (2014): $80M with participation from Synthetic Genomics, Illumina, Draper Fisher Jurvetson (DFJ), Daniel Curran, and Celgene
Series B (2016): $220M led by Illumina, GE Ventures, and Celgene
Other Financing Round (2019): $30M supported by Emerging Technology Partners
Debt (2020): $1M featuring PPP
Series B (2024): $39.8M backed by Emerging Technology Partners, TVM Capital Healthcare Partners, and Panacea Ventures
Key Investors in Human Longevity
Emerging Technology Partners
ETP Capital is a life sciences-focused investment fund founded in 2000, dedicated to providing capital and support for the development and commercialization of innovative diagnostic and therapeutic products in the biomedical industry.
TVM Capital Healthcare Partners
TVM Capital Healthcare is an emerging markets-focused healthcare private equity investment firm. The organization invests growth capital and focuses on specialized healthcare services, digital health solutions, pharmaceuticals, medical devices, and diagnostics.
Panacea Ventures
Panacea Capital is a global healthcare venture fund focused on driving innovation in the biotech sector. The firm is dedicated to transforming lives through investments in life sciences, with a portfolio that includes over 30 private and several public companies.
What's next for Human Longevity?
With a substantial financial backing and a clear strategy for international growth, Human Longevity is positioned for significant scaling. The company's focus on precision medicine and healthy aging aligns with increasing global demand for advanced healthcare solutions. Future developments are expected to center on expanding its market presence in key international regions and further developing its longevity-focused medical offerings, solidifying its role as a key player in the future of healthcare.
See full Human Longevity company page
